Raymond James lowered the firm’s price target on Bausch Health (BHC) to $8 from $9 and keeps a Market Perform rating on the shares. Bausch Health reported a “solid” Q1 overall, with adjusted EBITDA and revenue strength across all businesses except Bausch + Lomb (BLCO) and International, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns
- Bausch Health Earnings Call Highlights Growth and Challenges
- Cautious Outlook on Bausch Health: Sell Rating Amid Strategic Uncertainty and Tariff Concerns
- Bausch Health Reports Q1 2025 Financial Results
- Bausch Health Reports Strong Q1 2025 Results with Revenue Growth and Strategic Refinancing